for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

June 3 (Reuters) - Beigene Ltd:

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

* BEIGENE LTD - RECOMMENDED DOSE OF BRUKINSA IN CHINESE PACKAGE INSERT IS 160 MG TWICE DAILY TAKEN ORALLY WITH OR WITHOUT FOOD Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up